The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia

MS Marcolino, AL Ribeiro, NCD Clementino, MDP Nunes, MM Barbosa, MHCR Silva, HNS Bittencourt, Marcel Geleijnse, Eric Boersma

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)


To investigate cardiac effects of imatinib at an extended follow-up (median 12.4 months), 12 chronic myeloid leukemia patients underwent cardiac screening. No significant changes on the frequency of cardiovascular signs and symptoms, electrocardiographic abnormalities, echocardiographic measurements and BNP levels were observed. Median ejection fraction was 67% at baseline versus 68% at follow-up (median intra-patient change 0.5%). Median BNP levels were 8.3 versus 7.3 pg/mL (median intra-patient change 0.2 pg/mL). Troponin I measures were below the lower limit of detection, whereas strain measures were similar to healthy control. This pilot study suggests that it is probably safe to perform cardiac monitoring on an annual basis. (C) 2010 Elsevier Ltd. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)317-322
Number of pages6
JournalLeukemia Research
Issue number3
Publication statusPublished - 2011

Research programs

  • EMC COEUR-09

Cite this